New drug with enzalutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years or older.
- Have prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy.
- Must have already tried one new hormone treatment (like abiraterone or apalutamide) and it stopped working.
- Cannot have been treated with enzalutamide before.
- Must not have received certain other cancer treatments within the past 4 weeks (except standard hormone therapy).
- Must be in generally good health with normal liver, kidney, and blood function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for men with advanced prostate cancer that has stopped responding to standard hormone therapy or chemotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
This trial tests a new investigational medicine (TY-302) combined with abiraterone, a standard hormone-blocking drug, in men with metastatic castration-resistant prostate cancer. It aims to see if this combination can slow cancer growth after initial hormone therapy stops working.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
This study tests a new drug called CP-PCA07 combined with enzalutamide for men whose prostate cancer has stopped responding to enzalutamide or abiraterone. The goal is to see if the combination is safe and can help control the cancer.
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.